Femme et Homme
- | Pays :
- Russian Federation
- | Organes : -
- | Spécialités : -
Extrait
Assess the efficacy of a new drug (a receptor agonist that modulates the glutamatergic activity) in the treatment of schizophrenia. The primary objective of this study is to determine if a mGlu2/3 agonist dosed for 28 days is superior to placebo in the treatment of patients with schizophrenia as measured by the Positive and Negative Symptom Scales (PANSS) total score.
Critère d'inclusion
- Schizophrenia